Inside the CoreWeave stock deal
CoreWeave CEO Michael Intrator discusses the company acquiring Core Scientific in a $9B stock deal on 'The Clamam Countdown.'
Natera's 'Signatera' detects recurrence of cancer through a blood test
Natera CEO Steve Chapman discusses the evolution of the company over ten years and how the company helps cancer patients on 'The Claman Countdown.'
Expert reveals if it's time for investors to up their stock exposure
Citi Head of U.S. Equity Trading Strategy Stuart Kaiser discusses what investors should commit to on 'The Claman Countdown.'
Companies are looking for certainty amid tariffs, US Chamber of Commerce CEO says
U.S. Chamber of Commerce CEO Suzanne Clark explains how tariffs impact decisions of CEOs all over the county on 'The Claman Countdown.'
NASDAQ president: There is an enormous amount of enthusiasm
NASDAQ President Nelson Griggs unpacks the IPO outlook and the pros of companies going public on 'The Claman Countdown.'
The 'big, beautiful bill' is overall a positive for the economy, Stephen Dover says
Franklin Templeton chief market strategist Stephen Dover unpacks the benefits of the 'big, beautiful bill' signed into law and the state of the U.S. economy under President Donald Trump on 'The Claman Countdown.'
Trump's 'big, beautiful bill' still needs to overcome these hurdles before passing
Fox News senior congressional correspondent Chad Pergram has the latest on the remaining hurdles to passing President Donald Trump's 'big, beautiful bill' on 'The Claman Countdown.'
The Senate put in an '11th-hour poison pill,' GOP lawmaker warns
Rep. Chip Roy, R-Texas, unpacks the debate over the passage of the 'big, beautiful bill' on 'The Claman Countdown.'
Banker compares knowing Trump tariff impact on economy to ‘driving through fog’
Richmond Federal Reserve Bank President and CEO Tom Barkin interprets impact of President Donald Trump’s economic policy on the market on ‘The Claman Countdown.’